UPCOMING DEADLINE ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Esperi...
February 14 2016 - 6:00AM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Eastern
District of Michigan on behalf of purchasers of Esperion
Therapeutics, Inc. (Nasdaq: ESPR) (“Esperion” or the “Company”)
common stock during the period between August 18, 2015 and
September 28, 2015, inclusive (the “Class Period”). Investors who
wish to become proactively involved in the litigation have until
March 14, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in common stock
purchased on or after August 18, 2015 and held through the
revelation of negative information during and/or at the end of the
Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Company common stock during the Class Period. Brower
Piven also encourages anyone with information regarding the
Company’s conduct during the period in question to contact the
firm, including whistleblowers, former employees, shareholders and
others.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that there was no clear
path to approval for ETC-1002, and that the U.S. Food and Drug
Administration (“FDA”) had encouraged the Company to initiate a
cardiovascular outcomes trial (“CVOT”), the completion of which
could be necessary prior to approval of ETC–1002.
According to the complaint, following the September 28, 2015
disclosure that Esperion reversed course about having a clear
regulatory path for the development and approval of ETC-1002, and
by revealing that the FDA had actually encouraged the Company to
initiate promptly a cardiovascular outcomes trial that may be
necessary prior to approval, the value of Esperion shares declined
significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160214005024/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024